Hardman, Clayton http://orcid.org/0000-0001-5275-7046
Ho, Stephen
Shimizu, Akira http://orcid.org/0000-0002-9475-9661
Luu-Nguyen, Quang http://orcid.org/0000-0003-3698-5270
Sloane, Jack L. http://orcid.org/0000-0002-2564-1002
Soliman, Mohamed S. A. http://orcid.org/0000-0003-1892-4917
Marsden, Matthew D. http://orcid.org/0000-0002-4857-8712
Zack, Jerome A. http://orcid.org/0000-0001-5486-8495
Wender, Paul A.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AI124763, CA31845, AI124743)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 11 February 2020
Accepted: 23 March 2020
First Online: 20 April 2020
Competing interests
: The authors declare the following competing interests. Stanford University has filed patent applications on this and related technology, which has been licensed by Neurotrope BioScience for the treatment of neurological disorders and by Bryologyx Inc. for use in HIV/AIDS eradication and cancer immunotherapy. P.A.W. is an advisor to both companies and a cofounder of the latter. J.A.Z. is on the scientific advisory board for BryoLogyx. The remaining authors declare no competing interests.